Denali Therapeutics Inc.
DNLIHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeDenali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company carries a $2.94B market cap, placing it firmly in the mid-cap category. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome).
Market Cap
$2.94B
Beta
1.02
P/E (TTM)
—
P/E (Fwd)
-7.62
EPS (TTM)
$-2.84
EPS (Fwd)
$-2.42
ROE
-54.9%
ROA
-29.1%
Cash
$710.5M
Total Debt
$37.7M
Free CF
-$268.5M
52W Change
13.6%
Annual Financials
Cash vs Debt
Where DNLI stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, DNLI finished 16.44% below its 150-day moving average ($21.59) and 14.74% below its 200-day moving average ($21.16). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is DNLI overbought or oversold?
At the October 20, 2026 close, DNLI's RSI(14) was 27.4, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Denali Therapeutics Inc. holds $710.5M in cash against $37.7M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$268.5M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -54.9% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $108.5M (2022) to $0 (2025), a 100% decline worth watching.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing DNLI.